Susan Branford

Prof Susan Branford

Centre for Cancer Biology

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Associate Professor Susan BranfordHead, Leukaemia Unit, Molecular and Genetic PathologyQualifications: PhD, University of South Australia, Fellow of the Faculty of Science (RCPA).Susan Branford holds the position of an Associate Professor at the School of Medicine and the School of Molecular and Biomedical Science of Adelaide University in Australia. She has special expertise in molecular monitoring of the BCR-ABL gene for patients with chronic myeloid leukaemia. As such she is a major contributor to international collaborative initiatives to establish guidelines and recommendations for producing reliable molecular data. Associate Professor Branford's main research is focused on the formation of the BCR-ABL gene, the mechanisms of kinase inhibitor drug resistance and the factors that predict for response to therapy and the development of drug resistance.VIDEOS:The importance of Molecular Monitoring in CMLDecember 2011, ICMLfThe importance of BCR-ABL kinase domain mutation analysis in CMLDecember 2011, ICMLfTranscript typing in CML patients April 26, 2010, OncUViewTVTKI therapy for CML April 26, 2010, OncUViewTVImatinib therapy for CML April 23 2010, OncUViewTVInternational reporting scale for CML patients 13 avril 2010, OncUViewTV

Year Citation
2026 Maqsood, M., Toubia, J., Wadham, C., Shanmuganathan, N., Shahrin, N. H., Fernandes, A., . . . Branford, S. (2026). Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing Data. Journal of Molecular Diagnostics, 28(1), 39-52.
DOI
2025 Toubia, J., Kusay, Y., Maqsood, M., Warnock, N. I., Lawrence, D. M., Bracken, C. P., . . . Schreiber, A. W. (2025). TRanscriptome ANalysis of StratifiEd CohorTs (TRANSECT) enables automated assessment of global gene regulation linked to disparate expression in user defined genes and gene sets. NAR Genomics and Bioinformatics, 7(2), lqaf041-1-lqaf041-13.
DOI
2025 Shanmuganathan, N., Yeung, D. T., Wadham, C., Fernandes, A., Maqsood, M., Shahrin, N. H., . . . Branford, S. (2025). Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Blood, 146(23), 2821-2832.
DOI
2025 Metzler, M., Branford, S., Hijiya, N., & Sakamoto, K. (2025). Old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia. British Journal Of Haematology, online(5), 1-7.
DOI
2024 Branford, S., Fernandes, A., Shahrin, N. H., Maqsood, M., Shanmuganathan, N., & Wadham, C. (2024). Beyond BCR::ABL1-the role of genomic analyses in the management of CML. Journal of the National Comprehensive Cancer Network : JNCCN, 22(1), 1-9.
DOI Scopus9 WoS9 Europe PMC6
2024 Hong, L. E., Wechalekar, M. D., Kutyna, M. M., Small, A., Lim, K., Thompson-Peach, C. A., . . . Hiwase, D. K. (2024). IDH-Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation. Blood, 143(18), 1873-1877.
DOI Scopus11 WoS11 Europe PMC10
2024 Kantarjian, H., Branford, S., Breccia, M., Cortes, J., Haddad, F. G., Hochhaus, A., . . . Xavier-Mahon, F. (2024). Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia, 38(5), 947-950.
DOI Scopus12 WoS10 Europe PMC7
2024 Kockerols, C., Valk, P. J. M., Dulucq, S., Nicolini, F. E., Branford, S., & Westerweel, P. E. (2024). BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: an individual participant data meta-analysis. American Journal of Hematology, 99(8), 1632-1635.
DOI Scopus8 WoS8 Europe PMC8
2024 Kok, C. H., Irani, Y., Clarson, J., Saunders, V., Dang, P., Shanmuganathan, N., . . . Hughes, T. P. (2024). CD302 predicts achievement of deep molecular response in chronic myeloid leukemia patients treated with imatinib. Blood Neoplasia, 1(2, article no. 100014), 1-11.
DOI Scopus1 Europe PMC1
2024 Zerella, J. R., Homan, C. C., Arts, P., Lin, X., Spinelli, S. J., Venugopal, P., . . . Hahn, C. N. (2024). Germline ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood, 144(17), 1765-1780.
DOI Scopus9 WoS8 Europe PMC6
2024 Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., & Hughes, T. P. (2024). Asciminib Monotherapy as frontline treatment of chronic-phase chronic Myeloid Leukemia: results from the ASCEND Study. Blood Journal, 144(9), 1933-2001.
DOI Scopus17 WoS14 Europe PMC12
2024 Kok, C. H., Saunders, V. A., Shanmuganathan, N., Liu, L., Irani, Y. D., Clarson, J., . . . Ross, D. M. (2024). Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia. BLOOD, 144(Supplement 1), 993-995.
DOI WoS2
2023 Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J. -M., Deininger, M., Fabarius, A., . . . Soverini, S. (2023). European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. LEUKEMIA, 37(11), 2150-2167.
DOI WoS64
2023 Irani, Y. D., Kok, C. H., Clarson, J., Shanmuganathan, N., Branford, S., Yeung, D. T., . . . Yong, A. S. (2023). Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Advances, 7(11), 2364-2374.
DOI Scopus15 WoS14 Europe PMC13
2023 Radich, J. P., Wall, M., Branford, S., Campbell, C. D., Chaturvedi, S., DeAngelo, D. J., . . . Druker, B. J. (2023). Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica, 108(6), 1567-1578.
DOI Scopus3 WoS4 Europe PMC4
2023 Shanmuganathan, N., Wadham, C., Shahrin, N., Feng, J., Thomson, D., Wang, P., . . . Branford, S. (2023). Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica, 108(9), 2380-2395.
DOI Scopus19 WoS18 Europe PMC15
2023 Irani, Y. D., Hughes, A., Kok, C. H., Clarson, J., Yeung, D. T., Ross, D. M., . . . Yong, A. S. M. (2023). Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. British Journal of Haematology, 202(6), 1127-1136.
DOI Scopus6 WoS4 Europe PMC4
2023 Pagani, I. S., Shanmuganathan, N., Dang, P., Saunders, V. A., Grose, R., Kok, C. H., . . . Ross, D. M. (2023). Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy. Blood, 142(25), 2192-2197.
DOI Scopus8 WoS8 Europe PMC7
2023 Kok, C. H., Saunders, V. A., Dang, P., Shanmuganathan, N., White, D., Branford, S., . . . Hughes, T. P. (2023). Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer Journal, 13(1), 1-9.
DOI Scopus2 WoS2 Europe PMC1
2023 Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J. M., Deininger, M., Fabarius, A., . . . Soverini, S. (2023). European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia, 37(11), 2150-2167.
DOI Scopus67 Europe PMC60
2022 Branford, S. (2022). BCR::ABL1 transcripts and clinical outcome - interrogating the technique. British Journal of Haematology, 197(1), 9-10.
DOI Scopus3 WoS2 Europe PMC2
2022 Fernandes, A., Shanmuganathan, N., & Branford, S. (2022). Genomic mechanisms influencing outcome in chronic myeloid leukemia. Cancers, 14(3), 620-1-620-20.
DOI Scopus16 WoS13 Europe PMC11
2022 Adnan Awad, S., Brück, O., Shanmuganathan, N., Jarvinen, T., Lähteenmäki, H., Klievink, J., . . . Mustjoki, S. (2022). Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer Journal, 12(4, article no. 69), 4 pages.
DOI Scopus22 WoS19 Europe PMC14
2022 Shanmuganathan, N., Wadham, C., Thomson, D., Shahrin, N. H., Vignaud, C., Obourn, V., . . . Branford, S. (2022). RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia.. The Journal of molecular diagnostics : JMD, 24(7), 803-822.
DOI Scopus9 WoS6 Europe PMC5
2022 Lu, L., Kok, C. H., Dang, P., Branford, S., Saunders, V. A., Shanmuganathan, N., . . . Yeung, D. T. O. (2022). Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. British Journal of Haematology, 198(3), 600-603.
DOI Scopus9 WoS8 Europe PMC7
2022 Branford, S. (2022). Initial rate of BCR::ABL1 decline for response prediction in chronic myeloid leukemia. Turkish Journal of Hematology, 39(3), 204-205.
DOI
2022 Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Branford, S., & Tefferi, A. (2022). International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood, 140(11), 1200-1228.
DOI Scopus2064 WoS1906 Europe PMC1715
2022 Shahrin, N. H., Wadham, C., & Branford, S. (2022). Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication.. Current hematologic malignancy reports, 264(6), 171-180.
DOI Scopus8 WoS5 Europe PMC4
2022 Krishnan, V., Kim, D. D. H., Hughes, T. P., Branford, S., & Ong, S. T. (2022). Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica, 107(2), 358-370.
DOI Scopus17 WoS15 Europe PMC14
2022 Shanmuganathan, N., & Branford, S. (2022). Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing. British Journal of Haematology, 196(1), 19-30.
DOI Scopus2 WoS4 Europe PMC3
2022 Duncavage, E. J., Bagg, A., Hasserjian, R. P., DiNardo, C. D., Godley, L. A., Iacobucci, I., . . . Cazzola, M. (2022). Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood, 140(21), 2228-2247.
DOI Scopus164 WoS155 Europe PMC137
2022 Branford, S., & Apperley, J. F. (2022). Measurable residual disease in chronic myeloid leukemia.. Haematologica, 107(12), 2794-2809.
DOI Scopus14 WoS14 Europe PMC14
2021 Ochi, Y., Yoshida, K., Huang, Y. -J., Kuo, M. -C., Nannya, Y., Sasaki, K., . . . Shih, L. -Y. (2021). Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun, 12(1), 2833-1-2833-13.
DOI Scopus69 WoS63 Europe PMC50
2021 Branford, S. (2021). Taming the gatekeeper: ponatinib dose holds the key. Blood, 138(21), 2011-2012.
DOI
2021 Adnan Awad, S., Dufva, O., Ianevski, A., Ghimire, B., Koski, J., Maliniemi, P., . . . Mustjoki, S. (2021). RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia, 35(4), 1087-1099.
DOI Scopus44 WoS40 Europe PMC38
2021 Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207.
DOI Scopus71 WoS62 Europe PMC49
2020 Branford, S. (2020). Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?. Haematologica, 105(12), 2730-2737.
DOI Scopus23 WoS19 Europe PMC18
2020 Schmitz, U., Shah, J. S., Dhungel, B. P., Monteuuis, G., Luu, P. -L., Petrova, V., . . . Rasko, J. E. J. (2020). Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients. Cancers, 12(12), 3738-1-3738-19.
DOI Scopus10 WoS10 Europe PMC11
2020 Thomson, D. W., Shahrin, N. H., Wang, P. P. S., Wadham, C., Shanmuganathan, N., Scott, H. S., . . . Branford, S. (2020). Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia, 34(8), 2051-2063.
DOI Scopus36 WoS34 Europe PMC29
2020 Pagani, I. S., Dang, P., Saunders, V. A., Braley, J., Thieleke, A., Branford, S., . . . Ross, D. M. (2020). Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leukemia and Lymphoma, 61(10), 2527-2529.
DOI Scopus9 WoS6 Europe PMC4
2020 Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., . . . Ross, D. M. (2020). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 34(4), 1052-1061.
DOI Scopus42 WoS41 Europe PMC33
2019 Shanmuganathan, N., Braley, J. A., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., . . . Branford, S. (2019). Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood, 134(1), 85-89.
DOI Scopus28 WoS25 Europe PMC19
2019 Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., . . . Hiwase, D. K. (2019). The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 33(12), 2842-2853.
DOI Scopus50 WoS48 Europe PMC44
2019 Baccarani, M., Castagnetti, F., Gugliotta, G., Rosti, G., Soverini, S., Albeer, A., . . . Bendit, I. (2019). The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. LEUKEMIA, 33(5), 1173-1183.
DOI WoS104 Europe PMC90
2019 Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., . . . International CML Foundation Genomics Alliance. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 33(8), 1835-1850.
DOI Scopus115 WoS102 Europe PMC94
2019 Sharplin, K., Altamura, H., Taylor, K., Wellwood, J., Taylor, D., & Branford, S. (2019). Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript. Leukemia Research, 87(106231), 106231.
DOI Scopus8 WoS6 Europe PMC5
2019 Shanmuganathan, N., & Branford, S. (2019). The hidden pathogenesis of CML: is BCR-ABL1 the first event?. Current Hematologic Malignancy Reports, 14(6), 481-491.
DOI Scopus11 WoS8 Europe PMC9
2019 Shanmuganathan, N., Branford, S., Hughes, T. P., & Hiwase, D. (2019). Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Advances, 3(3), 370-374.
DOI Scopus7 WoS6 Europe PMC3
2019 Magistroni, V., Mauri, M., D'Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., . . . Piazza, R. (2019). De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. Haematologica, 104(9), 1789-1797.
DOI Scopus24 WoS23 Europe PMC21
2019 Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., . . . Yong, A. S. M. (2019). Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 186(3), e56-e60.
DOI Scopus13 WoS12 Europe PMC12
2018 Lasica, M., Willcox, A., Burbury, K., Ross, D. M., Branford, S., Butler, J., . . . Grigg, A. (2018). The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leukemia and Lymphoma, OnlinePubl(7), 1-7.
DOI Scopus22 WoS17 Europe PMC14
2018 Ross, D., Pagani, I., Shanmuganathan, N., Kok, C., Seymour, J., Mills, A., . . . Hughes, T. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 32(12), 2572-2579.
DOI Scopus69 WoS63 Europe PMC57
2018 Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., . . . Hughes, T. P. (2018). Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 132(9), 948-961.
DOI Scopus169 WoS158 Europe PMC145
2018 Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., . . . Ross, D. M. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica, 103(12), 2026-2032.
DOI Scopus36 WoS28 Europe PMC24
2018 Eadie, L., Saunders, V., Branford, S., White, D., & Hughes, T. (2018). The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget, 9(17), 13423-13437.
DOI Scopus48 Europe PMC35
2018 Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., . . . Hughes, T. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leukemia Research, 67, 109-115.
DOI Scopus15 WoS15 Europe PMC9
2017 Hochhaus, A., Larson, R., Guilhot, F., Radich, J., Branford, S., Hughes, T., . . . Druker, B. (2017). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine, 376(10), 917-927.
DOI Scopus1055 WoS945 Europe PMC800
2017 Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan Jacob, S. W., Branford, S., & Sellers, W. R. (2017). The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 543(7647), 733-737.
DOI Scopus484 WoS460 Europe PMC395
2017 Casolari, D., Nguyen, T., Butcher, C., Iarossi, D., Hahn, C., Bray, S., . . . D'Andrea, R. (2017). A novel, somatic, transforming mutation in the extracellular domain of epidermal growth factor receptor identified in myeloproliferative neoplasm. Scientific Reports, 7(1), 2467-1-2467-9.
DOI Scopus6 WoS6 Europe PMC7
2017 Marum, J., Yeung, D., Purins, L., Reynolds, J., Parker, W., Stangl, D., . . . Branford, S. (2017). ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Advances, 1(18), 1369-1381.
DOI Scopus21 WoS17 Europe PMC20
2017 Hughes, T. P., Leber, B., Cervantes, F., Spector, N., Pasquini, R., Clementino, N. C. D., . . . Lipton, J. H. (2017). Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: Final ENESTcmr randomized trial results. Leukemia, 31(11), 2529-2531.
DOI Scopus41 WoS41 Europe PMC31
2017 Ma, L., Boucher, J., Paulsen, J., Matuszewski, S., Eide, C., Ou, J., . . . Bolon, D. (2017). CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proceedings of the National Academy of Sciences of the United States of America, 114(44), 11751-11756.
DOI Scopus55 WoS46 Europe PMC47
2016 Branford, S. (2016). Molecular monitoring in chronic myeloid leukemia - How low can you go?. Hematology, 2016(1), 156-163.
DOI Scopus23 WoS22 Europe PMC19
2016 Marum, J. E., & Branford, S. (2016). Current developments in molecular monitoring in chronic myeloid leukemia. THERAPEUTIC ADVANCES IN HEMATOLOGY, 7(5), 237-251.
DOI WoS21 Europe PMC19
2016 Branford, S. (2016). Monitoring and defining early response: Where to draw the line?. Best Practice and Research: Clinical Haematology, 29(3), 284-294.
DOI Scopus7 WoS7 Europe PMC4
2016 Torra, O. S., Beppu, L., Smith, J. L., Welden, L., Georgievski, J., Gupta, K., . . . Radich, J. P. (2016). Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots. Blood, 127(22), 2773-2774.
DOI Scopus18 WoS19 Europe PMC16
2016 Cross, N., White, H., Ernst, T., Welden, L., Dietz, C., Saglio, G., . . . Branford, S. (2016). Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia, 30(9), 1844-1852.
DOI Scopus52 WoS44 Europe PMC35
2016 Yoshida, C., Nakamae, H., Fletcher, L., Koga, D., Sogabe, T., Matsumura, I., . . . Naoe, T. (2016). Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale. SpringerPlus, 5(1), 569-1-569-7.
DOI Scopus4 WoS3 Europe PMC3
2016 Deininger, M., Hodgson, J., Shah, N., Cortes, J., Kim, D., Nicolini, F., . . . Branford, S. (2016). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 127(6), 703-712.
DOI Scopus94 WoS90 Europe PMC69
2016 Parker, W., Yeung, D., Yeoman, A., Altamura, H., Jamison, B., Field, C., . . . Branford, S. (2016). The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood, 127(15), 1870-1880.
DOI Scopus60 WoS57 Europe PMC51
2016 Latham, S., Bartley, P., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2016). BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. Journal of Clinical Pathology, 69(9), 817-821.
DOI Scopus9 WoS9 Europe PMC7
2016 Ross, D. M., Altamura, H. K., Hahn, C. N., Nicola, M., Yeoman, A. L., Holloway, M. R., . . . Scott, H. S. (2016). Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. Leukemia, 30(6), 1402-1405.
DOI Scopus9 WoS9 Europe PMC8
2015 Yeung, D., Tang, C., Vidovic, L., White, D., Branford, S., Hughes, T., & Yong, A. (2015). KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. Blood, 126(25), 2720-2723.
DOI Scopus27 WoS24 Europe PMC23
2015 Enjeti, A., Granter, N., Ashraf, A., Fletcher, L., Branford, S., Rowlings, P., & Dooley, S. (2015). A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system. Pathology, 47(6), 570-574.
DOI Scopus12 WoS13 Europe PMC10
2015 Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . . . Hughes, T. (2015). TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923.
DOI Scopus91 WoS76 Europe PMC67
2015 Bartley, P., Latham, S., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2015). A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. The Journal of Molecular Diagnostics, 17(2), 185-192.
DOI Scopus23 WoS18 Europe PMC17
2015 Yeung, D. T., Moulton, D. J., Heatley, S. L., Nievergall, E., Dang, P., Braley, J., . . . White, D. L. (2015). Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia, 29(1), 230-232.
DOI Scopus27 WoS22 Europe PMC21
2014 Branford, S., Yeung, D., Parker, W., Roberts, N., Purins, L., Braley, J., . . . Hughes, T. (2014). Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood, 124(4), 511-518.
DOI Scopus192 WoS159 Europe PMC143
2014 Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2014). Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood, 124(1), 153-155.
DOI Scopus28 WoS26 Europe PMC23
2014 Hughes, T., Lipton, J., Spector, N., Cervantes, F., Pasquini, R., Clementino, N., . . . Leber, B. (2014). Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood, 124(5), 729-736.
DOI Scopus86 WoS76 Europe PMC68
2014 Baccarani, M., Druker, B., Branford, S., Kim, D., Pane, F., Mongay, L., . . . Guilhot, F. (2014). Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology, 99(5), 616-624.
DOI Scopus45 WoS39 Europe PMC36
2014 Olshen, A., Tang, M., Cortes, J., Gonen, M., Hughes, T., Branford, S., . . . Michor, F. (2014). Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica, 99(11), 1701-1709.
DOI Scopus14 WoS9 Europe PMC10
2014 Soverini, S., Branford, S., Nicolini, F. E., Talpaz, M., Deininger, M. W. N., Martinelli, G., . . . Shah, N. P. (2014). Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leukemia Research, 38(1), 10-20.
DOI Scopus157 WoS143 Europe PMC119
2014 Branford, S., Ross, D. M., Yeung, D. T., Braley, J., & Hughes, T. P. (2014). Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint. Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 124(21), 4561.
WoS2
2014 Branford, S. (2014). Digging into the power system: The growth of indigenous movements in Ecuador and Bolivia. Index on Censorship, 43(4), 43-46.
DOI
2013 Carella, A. M., Branford, S., Deininger, M., Mahon, F. X., Saglio, G., Eiring, A., . . . Goldman, J. M. (2013). What challenges remain in chronic myeloid leukemia research?. Haematologica, 98(8), 1168-1172.
DOI Scopus14 WoS13 Europe PMC11
2013 Stein, A., Martinelli, G., Hughes, T., Muller, M., Beppu, L., Gottardi, E., . . . Radich, J. (2013). Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 13(1), 1-10.
DOI Scopus15 WoS14 Europe PMC13
2013 Parker, W., Yeoman, A., Jamison, B., Yeung, D., Scott, H., Hughes, T., & Branford, S. (2013). BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. British Journal of Cancer, 109(6), 1593-1598.
DOI Scopus22 WoS18 Europe PMC16
2013 Ross, D., Branford, S., Seymour, J., Schwarer, A., Arthur, C., Yeung, D., . . . Hughes, T. (2013). Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122(4), 515-522.
DOI Scopus638 WoS600 Europe PMC539
2013 Branford, S., Yeung, D., Ross, D., Prime, J., Field, C., Altamura, H., . . . Hughes, T. (2013). Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 121(19), 3818-3824.
DOI Scopus152 WoS144 Europe PMC131
2013 Roberts, N., Kortschak, R., Parker, W., Schreiber, A., Branford, S., Scott, H., . . . Adelson, D. (2013). A comparative analysis of algorithms for somatic SNV detection in cancer. Bioinformatics, 29(18), 2223-2230.
DOI Scopus80 WoS79 Europe PMC73
2013 White, H., Hedges, J., Bendit, I., Branford, S., Colomer, D., Hochhaus, A., . . . Labourier, E. (2013). Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clinical Chemistry, 59(6), 938-948.
DOI Scopus45 WoS38 Europe PMC35
2012 Branford, S., Kim, D., Soverini, S., Haque, A., Shou, Y., Woodman, R., . . . Muller, M. (2012). Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with Nilotinib. Journal of Clinical Oncology, 30(35), 4323-4329.
DOI Scopus86 WoS80 Europe PMC70
2012 Branford, S. (2012). Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26(9), 2096-2102.
DOI Scopus367 WoS336 Europe PMC307
2012 Branford, S., Yeung, D., Prime, J., Choi, S., Bang, J., Park, J., . . . Hughes, T. (2012). BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood, 119(18), 4264-4271.
DOI Scopus44 WoS44 Europe PMC38
2012 Balasubramanian, P., Chendamarai, E., Markose, P., Fletcher, L., Branford, S., George, B., . . . Srivastava, A. (2012). International Reporting Scale of BCR-ABL1 Fusion Transcript in Chronic Myeloid Leukemia: First Report from India. Acta Haematologica, 127(3), 135-142.
DOI Scopus6 WoS7 Europe PMC7
2012 Parker, W., Ho, M., Scott, H., Hughes, T., & Branford, S. (2012). Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood, 119(10), 2234-2238.
DOI Scopus64 WoS57 Europe PMC51
2012 Yeung, D., & Branford, S. (2012). Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?. Hematology, the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012(1), 111-114.
DOI Scopus2 WoS2 Europe PMC2
2012 Yoshida, C., Fletcher, L., Ohashi, K., Wakita, H., Kumagai, T., Shiseki, M., . . . Sakamaki, H. (2012). Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. International Journal of Clinical Oncology, 17(6), 584-589.
DOI Scopus28 WoS28 Europe PMC25
2012 Branford, S. (2012). Continued therapeutic response monitoring in optimal responders with CML. Clinical Advances in Hematology and Oncology, 10(12), 819-821.
Scopus1
2012 Branford, S. (2012). Monitoring after successful therapy for chronic myeloid leukemia.. Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2012, 105-110.
DOI Scopus8 WoS7 Europe PMC1
2011 Esposito, N., Colavita, I., Quintarelli, C., Sica, A., Peluso, A., Luciano, L., . . . Pane, F. (2011). SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood, 118(13), 3634-3644.
DOI Scopus48 WoS41 Europe PMC38
2011 Brown, J., Laosinchai-Wolf, W., Hedges, J., Watt, C., Van Deerlin, V., Fletcher, L., . . . Labourier, E. (2011). Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale. Blood Cancer Journal, 1(3), E13.
DOI Scopus15 WoS14 Europe PMC14
2011 Stein, A., Bottino, D., Modur, V., Branford, S., Kaeda, J., Goldman, J., . . . Hochhaus, A. (2011). BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatment. Clinical Cancer Research, 17(21), 6812-6821.
DOI Scopus39 WoS36 Europe PMC33
2011 Parker, W., Lawrence, R., Ho, M., Irwin, D., Scott, H., Hughes, T., & Branford, S. (2011). Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapy. Journal of Clinical Oncology, 29(32), 4250-4259.
DOI Scopus82 WoS75 Europe PMC72
2011 Yeung, D., Parker, W., & Branford, S. (2011). Molecular methods in diagnosis and monitoring of haematological malignancies. Pathology, 43(6), 566-579.
DOI Scopus15 WoS7 Europe PMC7
2011 Tang, M., Gonen, M., Quintas-Cardama, A., Cortes, J., Kantarjian, H., Field, C., . . . Michor, F. (2011). Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood, 118(6), 1622-1631.
DOI Scopus57 WoS54 Europe PMC50
2011 Branford, S., & Hughes, T. (2011). Mutational analysis in chronic myeloid leukemia: When and what to do?. Current Opinion in Hematology, 18(2), 111-116.
DOI Scopus20 WoS22 Europe PMC19
2011 Branford, S., & Prime, J. (2011). Chronic myelogenous leukemia: Monitoring response to therapy. Current Hematologic Malignancy Reports, 6(2), 75-81.
DOI Scopus6 WoS5 Europe PMC4
2011 Ross, D., & Branford, S. (2011). Minimal residual disease: the advantages of digital over analog polymerase chain reaction. Leukemia & Lymphoma, 52(7), 1161-1163.
DOI Scopus6 WoS5 Europe PMC3
2011 Jabbour, E., Branford, S., Saglio, G., Jones, D., Cortes, J., & Kantarjian, H. (2011). Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer, 117(9), 1800-1811.
DOI Scopus79 WoS67 Europe PMC58
2010 Branford, S., & Hughes, T. (2010). Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 116(22), E111-E117.
DOI Scopus155 WoS122 Europe PMC99
2010 Hughes, T., Hochhaus, A., Branford, S., Muller, M., Kaeda, J., Foroni, L., . . . Radich, J. (2010). Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 116(19), 3758-3765.
DOI Scopus433 WoS374 Europe PMC333
2010 Bartley, P., Ross, D., Latham, S., Martin-Harris, M., Budgen, B., Wilczek, V., . . . Morley, A. (2010). Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. International Journal of Laboratory Hematology (Print Edition), 32(6 Part 1), E222-E228.
DOI Scopus52 WoS42 Europe PMC38
2010 Ross, D., Branford, S., Seymour, J., Schwarer, A., Arthur, C., Bartley, P., . . . Hughes, T. (2010). Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 24(10), 1719-1724.
DOI Scopus248 WoS214 Europe PMC199
2010 Branford, S., & Hughes, T. (2010). Practical considerations for monitoring patients with chronic myeloid leukemia. Seminars in Hematology, 47(4), 327-334.
DOI Scopus7 WoS5 Europe PMC5
2010 Cortes, A., Baccarani, M., Guilhot, F., Druker, B., Branford, S., Kim, D., . . . Hughes, T. (2010). Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. Journal of Clinical Oncology, 28(3), 424-430.
DOI Scopus244 WoS230 Europe PMC203
2010 Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., . . . Larson, R. A. (2010). Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38). Leukemia, 24(5), 1102.
DOI Scopus2 WoS7
2009 Branford, S., Vaz de Melo, J., & Hughes, T. (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood, 114(27), 5426-5435.
DOI Scopus159 WoS136 Europe PMC130
2009 Muller, M., Cortes, J., Kim, D., Druker, B., Erben, P., Pasquini, R., . . . Hochhaus, A. (2009). Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood, 114(24), 4944-4953.
DOI Scopus259 WoS262 Europe PMC207
2009 Hughes, T., & Branford, S. (2009). Measuring minimal residual disease in chronic myeloid leukemia: Fluorescence in situ hybridization and polymerase chain reaction. Clinical Lymphoma & Myeloma, 9(Supp 3), S266-S271.
DOI Scopus8 WoS3 Europe PMC4
2009 Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, J., Muller, M., . . . Hochhaus, A. (2009). Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology, 27(25), 4204-4210.
DOI Scopus280 WoS259 Europe PMC229
2009 Muller, M., Cross, N., Erben, P., Schenk, T., Hanfstein, B., Ernst, T., . . . Hochhaus, A. (2009). Harmonization of molecular monitoring of CML therapy in Europe. Leukemia, 23(11), 1957-1963.
DOI Scopus193 WoS171 Europe PMC157
2009 Ross, D., Branford, S., Melo, J., & Hughes, T. (2009). Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin. Leukemia, 23(4), 819-820.
DOI Scopus7 WoS8 Europe PMC5
2009 Hochhaus, A., Muller, M., Radich, J., Branford, S., Kantarjian, H., Hanfstein, B., . . . Hughes, T. (2009). Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia, 23(9), 1628-1633.
DOI Scopus33 WoS32 Europe PMC28
2009 Hochhaus, A., O'Brien, S., Guilhot, F., Druker, B., Branford, S., Foroni, L., . . . Larson, R. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23(6), 1054-1061.
DOI Scopus764 WoS673 Europe PMC613
2009 Tojo, A., Usuki, K., Urabe, A., Maeda, Y., Kobayashi, Y., Jinnai, I., . . . Naoe, T. (2009). A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL. International Journal of Hematology, 89(5), 679-688.
DOI Scopus39 WoS38 Europe PMC31
2009 Ross, D., Schafranek, L., Hughes, T., Nicola, M., Branford, S., & Score, J. (2009). Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification. Cancer Genetics and Cytogenetics, 189(2), 138-139.
DOI Scopus6 WoS6 Europe PMC6
2009 Hughes, T. P., & Branford, S. (2009). Monitoring disease response to tyrosine kinase inhibitor therapy in CML.. Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2009(1), 477-487.
DOI Scopus61 Europe PMC35
2008 Branford, S., Fletcher, L., Cross, N. C. P., Müller, M. C., Hochhaus, A., Kim, D. W., . . . Hughes, T. (2008). Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 112(8), 3330-3338.
DOI Scopus346 WoS314 Europe PMC282
2008 Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., . . . Grigg, A. (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy. Blood, 112(10), 3965-3973.
DOI Scopus148 WoS137 Europe PMC131
2008 Ross, D., Watkins, D., Hughes, T., & Branford, S. (2008). Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease. Clinical Chemistry, 54(9), 1568-1571.
DOI Scopus11 WoS11 Europe PMC9
2008 Saglio, G., Radich, J., Kim, D., Martinelli, G., Branford, S., Mueller, M., . . . Hughes, T. (2008). Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
DOI WoS5
2007 Saldanha, J., Silvy, M., Beaufils, N., Arlinghaus, R., Barbany, G., Branford, S., . . . Gabert, J. (2007). Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: Towards new standards for gene expression measurements. Leukemia, 21(7), 1481-1487.
DOI Scopus26 WoS22 Europe PMC22
2007 Guilhot, F., Apperley, J., Kim, D. W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., . . . Talpaz, M. (2007). Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109(10), 4143-4150.
DOI Scopus345 WoS290 Europe PMC244
2007 Cortes, J., Rousselot, P., Kim, D. W., Ritchie, E., Hamerschlak, N., Coutre, S., . . . Baccarani, M. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109(8), 3207-3213.
DOI Scopus395 WoS328 Europe PMC266
2007 Hughes, T., & Branford, S. (2007). Ph+ ALL: Resistance seeds sown early. Blood, 110(2), 472.
DOI
2007 Branford, S., Seymour, J., Grigg, A., Arthur, C., Rudzki, Z., Lynch, K., & Hughes, T. (2007). BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clinical Cancer Research, 13(23), 7080-7085.
DOI Scopus122 WoS110 Europe PMC100
2007 Hughes, T., Branford, S., & Goldman, J. (2007). Reliability of PCR for BCR-ABL transcripts. Blood, 109(5), 2263-2264.
DOI WoS1
2007 Branford, S., Hughes, T., Milner, A., Koelmeyer, R., Schwarer, A., Arthur, C., . . . Taylor, K. (2007). Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α. Cancer, 110(4), 801-808.
DOI Scopus6 WoS7 Europe PMC4
2007 Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007). Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation, 117(9), 2562-2569.
DOI Scopus348 WoS331 Europe PMC297
2007 Branford, S. (2007). Chronic myeloid leukemia: molecular monitoring in clinical practice.. Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2007(1), 376-383.
DOI Scopus50 Europe PMC30
2006 Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., . . . Goldman, J. M. (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108(1), 28-37.
DOI Scopus1077 WoS954 Europe PMC811
2006 Hughes, T., & Branford, S. (2006). Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Reviews, 20(1), 29-41.
DOI Scopus133 WoS112 Europe PMC92
2006 Ross, D., Branford, S., Moore, S., & Hughes, T. (2006). Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia, 20(4), 664-670.
DOI Scopus63 WoS57 Europe PMC54
2006 Branford, S., Cross, N., Hochhaus, A., Radich, J., Saglio, G., Kaeda, J., . . . Hughes, T. (2006). Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia, 20(11), 1925-1930.
DOI Scopus178 WoS158 Europe PMC133
2006 Branford, S., & Hughes, T. (2006). Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR.. Methods in Molecular Medicine, 125, 69-92.
DOI Scopus50 Europe PMC39
2006 Branford, S., & Hughes, T. (2006). Detection of BCR-ABL mutations and resistance to imatinib mesylate.. Methods in Molecular Medicine, 125, 93-106.
DOI Scopus70 Europe PMC44
2005 Demehri, S., Paschka, P., Schultheis, B., Lange, T., Koizumi, T., Sugimoto, T., . . . Deininger, M. W. N. (2005). e8a2 BCR-ABL: More frequent than other atypical BCR-ABL variants? [5]. Leukemia, 19(4), 681-684.
DOI Scopus41 WoS38 Europe PMC31
2005 Michor, F., Hughes, T., Iwasa, Y., Branford, S., Shah, N., Sawyers, C., & Nowak, M. (2005). Dynamics of chronic myeloid leukaemia. Nature, 435(7046), 1267-1270.
DOI Scopus703 WoS644 Europe PMC536
2005 White, D., Saunders, V., Lyons, A., Branford, S., Grigg, A., To, L., & Hughes, T. (2005). In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.. Blood, 106(7), 2520-2526.
DOI Scopus124 WoS109 Europe PMC104
2004 Branford, S., Rudzki, Z., Parkinson, I., Grigg, A., Taylor, K., Seymour, J., . . . Hughes, T. (2004). Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood, 104(9), 2926-2932.
DOI Scopus206 WoS179 Europe PMC154
2004 Branford, S. (2004). Argentina's bitter harvest. New Scientist, 182(2443), 40-43.
Scopus13
2003 Branford, S., & Rocha, J. (2003). Another modernization is possible: From land conquest to agro-ecological experiment. Science as Culture, 12(2), 155-187.
DOI Scopus2
2003 Branford, S., Rudzki, Z., Harper, A., Grigg, A., Taylor, K., Durrant, S., . . . Hughes, T. (2003). Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 17(12), 2401-2409.
DOI Scopus149 WoS124 Europe PMC100
2003 Hughes, T., & Branford, S. (2003). Molecular monitoring of chronic myeloid leukemia. Seminars in Hematology, 40(2), 62-68.
DOI Scopus75 WoS61 Europe PMC47
2003 Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., . . . Hughes, T. (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102(1), 276-283.
DOI Scopus692 WoS598 Europe PMC503
2003 Hughes, T., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M., . . . Radich, J. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349(15), 1423-1432.
DOI Scopus1115 WoS976 Europe PMC819
2003 Hui, C., Goh, K., White, D., Branford, S., Grigg, A., Seymour, J., . . . Hughes, T. (2003). Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia, 17(5), 821-828.
DOI Scopus40 WoS33 Europe PMC31
2002 Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., . . . Hughes, T. (2002). High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99(9), 3472-3475.
DOI Scopus592 WoS534 Europe PMC448
2002 Branford, S., Hughes, T., & Rudzki, Z. (2002). Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. British Journal of Haematology, 117(4), 875-877.
DOI Scopus28 WoS26 Europe PMC17
2001 Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., . . . Hughes, T. (2001). Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivec non-responsive cases of CML.. BLOOD, 98(11), 769A-770A.
WoS4
2001 Branford, S., Moore, S., Grigg, A., Szer, J., Arthur, C., Taylor, K., . . . Hughes, T. (2001). Early measurement of BCR-ABL mRNA blood levels may be predictive of subsequent achievement of major cytogenetic response to Glivec in chronic myeloid leukemia.. BLOOD, 98(11), 613A.
WoS4
2000 Branford, S., Rudzi, Z., & Hughes, T. (2000). A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. British Journal of Haematology, 109(3), 635-637.
DOI Scopus45 WoS45 Europe PMC40
1999 Branford, S., Hughes, T., & Rudzki, Z. (1999). Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. British Journal of Haematology, 107(-), 587-599.
DOI Scopus210
1999 Branford, S., Rudzki, Z., & Hughes, T. P. (1999). Monitoring CML therapy by real-time Q-PCR in blood is a reliable alternative to marrow cytogenetics.. BLOOD, 94(10), 286A.
1999 Branford, S., Hughes, T. P., & Rudzki, Z. (1999). Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. BRITISH JOURNAL OF HAEMATOLOGY, 107(3), 587-599.
DOI WoS189 Europe PMC177
1996 Kee, P., Bais, R., Sobecki, S. K., Branford, S., Rye, K. A., & Barter, P. J. (1996). Indirect sandwich enzyme-linked immunosorbent assay (ELISA) for plasma apolipoprotein E. Annals of Clinical Biochemistry, 33(2), 119-126.
DOI Scopus3 WoS3 Europe PMC2
1992 Bais, R., Branford, S., & Sobecki, S. K. (1992). Reflotron method for high-density lipoprotein evaluated for venous and capillary blood [5]. Clinical Chemistry, 38(1), 164-166.
DOI

Year Citation
2025 Branford, S. (2025). Non-<i>ABL1 </i>Mutations in Newly Diagnosed Patients: Implications. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 25 (pp. S52-S53). CIG MEDIA GROUP, LP.
2024 Wechalekar, G., Cibich, A., Kutyna, M., Shanmuganathan, N., Sekaran, U. C., Singhal, D., . . . Hiwase, D. (2024). Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant. In BLOOD Vol. 144 (pp. 4928-4929). FL, Orlando: ELSEVIER.
DOI
2024 Branford, S., Fernandes, A., Wadham, C., Maqsood, M., Shahrin, N. H., Ross, D. M., . . . Shanmuganathan, N. (2024). Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure. In BLOOD Vol. 144 (pp. 996-997). FL, Orlando: ELSEVIER.
DOI WoS1
2024 Shanmuganathan, N., Wadham, C., Yeung, D., Shahrin, N. H., Fernandes, A., Maqsood, M., . . . Branford, S. (2024). Strong Association between Cancer Gene Variants at Diagnosis, Especially<i> ASXL1,</i> and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors. In BLOOD Vol. 144 (pp. 992). FL, Orlando: ELSEVIER.
DOI WoS5
2024 Yeung, D. T., Shanmuganathan, N., Yong, A. S. M., Shortt, J., Chee, L. C. Y., Vialla, N., . . . Hughes, T. P. (2024). Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare. In BLOOD Vol. 144 (pp. 477-478). FL, Orlando: ELSEVIER.
DOI WoS2
2024 Pagani, I. S., Krishnan, V., Ouyang, J., Kok, C. H., Chen, B., Page, E. C., . . . Ross, D. M. (2024). Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity. In BLOOD Vol. 144 (pp. 2715-2716). ELSEVIER.
DOI
2023 Branford, S., Wadham, C., Shanmuganathan, N., Fernandes, A., Shahrin, N. H., Feng, J., . . . Hughes, T. P. (2023). Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML. In BLOOD Vol. 142 (pp. 5 pages). CA, San Diego: ELSEVIER.
DOI WoS5
2023 Hong, L. E., Kok, C. H., Kutyna, M., Li, J. J., Chhetri, R., Ross, D. M., . . . Hiwase, D. (2023). High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: ELSEVIER.
DOI
2023 Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A. S. M., . . . Hughes, T. P. (2023). Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study. In BLOOD Vol. 142 (pp. 6 pages). CA, San Diego: ELSEVIER.
DOI
2023 Branford, S., Hochhaus, A., Mauro, M., Minami, Y., Rea, D., Boquimpani De Moura Freitas, C. M., . . . Hughes, T. P. (2023). Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors ( TKIs) in the Ascembl Trial. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: ELSEVIER.
DOI WoS2
2022 Hughes, T., Mauro, M., Branford, S., Deng, W., Wang, Q., Collins, H., & Hochhaus, A. (2022). First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies. In BLOOD Vol. 140 (pp. 6780-6781). LA, New Orleans: ELSEVIER.
DOI WoS1
2022 Shanmuganathan, N., Yeung, D. T., Wadham, C., Shahrin, N. H., Fernandes, A., Feng, J., . . . Branford, S. (2022). Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors. In BLOOD Vol. 140 (pp. 2 pages). LA, New Orleans: ELSEVIER.
DOI
2022 Branford, S., Shanmuganathan, N., Wadham, C., Shahrin, N. H., Fernandes, A., Feng, J., . . . Hughes, T. (2022). Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML. In BLOOD Vol. 140 (pp. 3916-3917). LA, New Orleans: ELSEVIER.
DOI WoS1
2022 Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A. S. M., . . . Hughes, T. (2022). Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML. In BLOOD Vol. 140 (pp. 3 pages). LA, New Orleans: ELSEVIER.
DOI
2021 Lu, L., Dang, P., HoowKok, C., Saunders, V. A., Branford, S., P.Hughes, T., & TYeung, D. (2021). Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER.
DOI WoS1
2020 Shanmuganathan, N., Wadham, C., Shahrin, N. H., Thomson, D., Feng, J., Saunders, V. A., . . . Branford, S. (2020). Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. In BLOOD Vol. 136 (pp. 4 pages). ELECTR NETWORK: ELSEVIER.
DOI WoS4
2020 Radich, J., Larson, R., Kantarjian, H., Deininger, M., Pinilla-Ibarz, J., DeAngelo, D., . . . Druker, B. (2020). Exploratory Biomarker Analysis from ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) from Poor Response in Chronic Myeloid Leukemia (CML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S233). CIG MEDIA GROUP, LP.
2019 Shanmuganathan, N., Thomson, D., Wadham, C., Saunders, V. A., Shahrin, N. H., Yeung, D. T., . . . Branford, S. (2019). RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS1
2019 Radich, J. P., Larson, R. A., Kantarjian, H. M., Deininger, M. W., Ibarz, J. P., DeAngelo, D. J., . . . Druker, B. J. (2019). Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd. In BLOOD Vol. 134 (pp. 5 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS2
2019 Branford, S., Wadham, C., Shanmuganathan, N., Thomson, D., Shahrin, N. U. R. H., Feng, J., . . . Hughes, T. P. (2019). An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). FL, Orlando: ELSEVIER.
DOI
2019 Branford, S., & Shanmuganathan, N. (2019). NGS in CML - new standard diagnostic procedure?. In HemaSphere Vol. 3 (pp. 48-50). US: Wolters Kluwer Health.
DOI Scopus7 WoS8 Europe PMC6
2019 Brown, A. L., Babic, M., Schreiber, A., Feng, J., Dobbins, J., Arts, P., . . . Scott, H. S. (2019). Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility. In BLOOD Vol. 134 (pp. 3 pages). FL, Orlando: ELSEVIER.
DOI
2019 Shahrin, N. H., Thomson, D., Wadham, C., Schreiber, A., & Branford, S. (2019). IMATINIB INDUCES MARKED UPREGULATION OF RECOMBINATION ACTIVATING GENE (RAG) EXPRESSION IN BCR-ABL1 POSITIVE LYMPHOID CELLS. In EXPERIMENTAL HEMATOLOGY Vol. 76 (pp. S85). ELSEVIER SCIENCE INC.
2018 Shanmuganathan, N., Branford, S., Yong, A., Hiwase, D., Yeung, D., Ross, D., & Hughes, T. (2018). Predictors of Success in Treatment-Free Remission: A Single Centre Experience. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S224). CIG MEDIA GROUP, LP.
DOI
2018 Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2018). Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. In BLOOD Vol. 132 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS7
2018 Thomson, D., Shahrin, H., Wang, P., Wadham, C., Hughes, T. P., Schreiber, A., & Branford, S. (2018). High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML. In BLOOD Vol. 132 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS2
2017 Branford, S., Wang, P., Yeung, D., Purins, A., Marum, J. E., Nataren, N., . . . Hughes, T. P. (2017). Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy. In BLOOD Vol. 130 (pp. 4 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2017 Shanmuganathan, N., Branford, S., Yeung, D., Hiwase, D. K., Yong, A. S. M., Ross, D. M., & Hughes, T. P. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology.
2017 Pagani, I., Dang, P., Kommers, I., Goyne, J., Saunders, V., Prime, J., . . . Ross, D. (2017). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. In Haematologica. Madrid: Ferrata Storti Foundation.
2016 Marum, J. E., Wang, P. P. S., Stangl, D., Yeung, D. T., Mueller, M. C., Dietz, C. T., . . . Branford, S. (2016). Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis. In BLOOD Vol. 128 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS2
2016 Shanmuganathan, N., Branford, S., Braley, J., Hiwase, D., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2016). For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR. In BLOOD Vol. 128 (pp. 7 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI
2016 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI
2016 Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . . . Hughes, T. P. (2016). Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. In BLOOD Vol. 128 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI
2016 Wang, P., Parker, W., Branford, S., & Schreiber, A. (2016). BAM-matcher: a tool for rapid NGS sample matching. In Bioinformatics Vol. 32 (pp. 2699-2701). UK: Oxford University Press.
DOI Scopus34 WoS32 Europe PMC35
2015 Hughes, T. P., Cervantes, F., Leber, B., Spector, N., Lipton, J. H., Pasquini, R., . . . Branford, S. (2015). ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL). In HAEMATOLOGICA Vol. 100 (pp. 61-62). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
2015 Hughes, T. P., Cervantes, F., Spector, N., Leber, B., Branford, S., Glynos, T. A., . . . Lipton, J. H. (2015). Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2015 Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2015 Yeung, D. T., Parker, W. T., Phillis, S., Georgievski, J., Scott, H. S., Hughes, T. P., & Branford, S. (2015). BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2015 Hahn, C. N., Babic, M., Schreiber, A. W., Kutyna, M. M., Wee, L. A., Brown, A. L., . . . Hiwase, D. (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS3
2015 Marum, J. E., Purins, L., Yeung, D. T., Parker, W. T., Price, D. J., Wang, P. P. S., . . . Branford, S. (2015). Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI
2015 Branford, S., Wang, P. P. S., Parker, W. T., Yeung, D., Marum, J. E., Stangl, D., . . . Hughes, T. P. (2015). High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2015 Smith, C. C., Paguirigan, A., Chin, C. -S., Brown, M., Parker, W., Levis, M. J., . . . Shah, N. P. (2015). Polyclonal and heterogeneous resistance to targeted therapy in leukemia. In CANCER RESEARCH Vol. 75 (pp. 3 pages). Philadelphia, PA: AMER ASSOC CANCER RESEARCH.
DOI
2014 Matsumura, I., Nakamae, H., Yoshida, C., Fletcher, L., Branford, S., Koga, D., . . . Naoe, T. (2014). Odk-1201, One-Step RT-qPCR Major <i>BCR-ABL/ABL</i> mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
2014 Magistroni, V., Piazza, R., Sharma, N., Parker, W., Pirola, A., Yeung, D., . . . Gambacorti-Passerini, C. (2014). IDENTIFICATION OF RECURRENT GENETIC ALTERATIONS ASSOCIATED WITH BLAST CRISIS TRANSFORMATION IN CHRONIC MYELOID LEUKEMIA. In HAEMATOLOGICA Vol. 99 (pp. 510-511). Milan, ITALY: FERRATA STORTI FOUNDATION.
2014 Deininger, M. W., Shah, N. P., Cortes, J. E., Kim, D. W., Nicolini, F. E., Talpaz, M., . . . Branford, S. (2014). LONGER-TERM FOLLOW-UP OF THE IMPACT OF BASELINE (BL) MUTATIONS ON PONATINIB RESPONSE AND END OF TREATMENT (EOT) MUTATION ANALYSIS IN PATIENTS (PTS) WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). In HAEMATOLOGICA Vol. 99 (pp. 533). Milan, ITALY: FERRATA STORTI FOUNDATION.
2014 Branford, S., Kamel-Reid, S., Bendit, I., Etienne, G., Guerci-Bresler, A., Hughes, T. P., . . . Cervantes, F. (2014). EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR. In HAEMATOLOGICA Vol. 99 (pp. 532). Milan, ITALY: FERRATA STORTI FOUNDATION.
WoS3
2013 Branford, S., Roberts, N., Yeung, D. T., Altamura, H., Parker, W. T., & Hughes, T. P. (2013). Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS9
2012 Ross, M., Branford, S., Seymour, J., Arthur, C., Schwarer, A., Dang, P., . . . Hughes, T. (2012). FREQUENT AND SUSTAINED DRUG-FREE REMISSION IN THE AUSTRALASIAN CML8 TRIAL OF IMATINIB WITHDRAWAL. In HAEMATOLOGICA Vol. 97 (pp. 74-75). FERRATA STORTI FOUNDATION.
WoS2
2012 Morley, A., Bartley, P., Latham, S., Budgen, B., Ross, D., Hughes, E., . . . Hughes, T. (2012). DNA-qPCR vs RT-qPCR for Monitoring MRD in Chronic Myeloid Leukemia. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 14 (pp. 662-663). Long Beach, CA: ELSEVIER SCIENCE INC.
2012 Smith, C. C., Brown, M., Parker, W. T., Lin, K., Travers, K., Wang, S., . . . Shah, N. (2012). Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy. In BLOOD Vol. 120 (pp. 2 pages). GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS9
2011 Hughes, T. P., Lipton, J. H., Leber, B., Spector, N., Cervantes, F., Pasquini, R., . . . Branford, S. (2011). Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. In BLOOD Vol. 118 (pp. 278). San Diego, CA: AMER SOC HEMATOLOGY.
WoS1
2011 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY.
WoS1
2011 le Coutre, P. D., Giles, F. J., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., . . . Kantarjian, H. M. (2011). Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study. In BLOOD Vol. 118 (pp. 1610). San Diego, CA: AMER SOC HEMATOLOGY.
WoS1
2011 Branford, S., Yeung, D. T., Prime, J., Ross, D., & Hughes, T. P. (2011). Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance. In BLOOD Vol. 118 (pp. 55). San Diego, CA: AMER SOC HEMATOLOGY.
WoS1
2011 Parker, W. T., Ho, M., Scott, H. S., Hughes, T. P., & Branford, S. (2011). Multiple Low Level Mutations Identifies Imatinib Resistant CML Patients At Risk of Poor Response to Second-Line Inhibitor Therapy, Irrespective of the Resistance Profile of the Mutations. In BLOOD Vol. 118 (pp. 54). San Diego, CA: AMER SOC HEMATOLOGY.
WoS1
2010 White, E., Matejtschuk, P., Rigsby, P., Gabert, J., Wang, Y., Branford, S., . . . Cross, N. (2010). ESTABLISHMENT OF THE 1ST WORLD HEALTH ORGANIZATION INTERNATIONAL GENETIC REFERENCE PANEL FOR QUANTITATION OF BCR-ABL MRNA. In HAEMATOLOGICA Vol. 95 (pp. 84-85). Barcelona, SPAIN: FERRATA STORTI FOUNDATION.
2010 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS10
2010 Parker, W., Ho, M., Lawrence, R., Irwin, D., Scott, H., Hughes, T., & Branford, S. (2010). Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistance. In Proceedings of 2010 american society of hematology meeting Vol. 116 (pp. 0 pages). Florida, USA: AMER SOC HEMATOLOGY.
2010 Prime, H., Romeo, G., Phillis, S., Field, C., Jamison, B., Prime, J., . . . Branford, S. (2010). Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivity. In Proceedings of Haematology association of australasia annual meeting (pp. 0 pages). Auckland, New Zealand.
2010 Branford, S., Goh, H., Izzo, B., Beppu, L., Ortmann, C., Duniec, K., . . . Hughes, T. (2010). A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate. In Proceedings of 52nd American Society of Hematology Meeting (ASH), as published in Blood Vol. 116 (pp. 389-390). Washington, DC: American Society of Hematology.
WoS1
2010 Fletcher, L., Prime, J., Phillis, S., Jamison, B., Field, C., Prime, H., . . . Branford, S. (2010). Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scale. In Proceedings of Haematology association of australasia annual meeting (pp. 0 pages). New Zealand.
2010 Branford, S., Martinelli, G., Saglio, G., Kim, D., Shou, Y., Reynolds, J., . . . Radich, J. (2010). Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib. In Proceedings of American society of clinical oncology conference Vol. 28 (pp. 0 pages). AMER SOC CLINICAL ONCOLOGY.
DOI WoS2
2010 Morley, A., Bartley, P., Ross, D., Latham, S., Budgen, B., Branford, S., & Hughes, T. (2010). Towards DNA-based monitoring of therapy in chronic myeloid leukemia. In Proceedings of 2010 American society of hematology meeting Vol. 116 (pp. 0 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2010 Kim, D., Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T., . . . Hochhaus, A. (2010). Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment. In Proceedings of 2010 American society of hematology meeting Vol. 116 (pp. 0 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2010 Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida.
2010 Saglio, S., Hughes, T., Kim, D., Hanfstein, B., Gottardi, E., Branford, S., . . . Martinelli, G. (2010). RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES. In HAEMATOLOGICA Vol. 95 (pp. 342-343). FERRATA STORTI FOUNDATION.
2010 Martinelli, G., Hochhaus, A., Radich, J., Soverini, S., Branford, S., Erben, P., . . . Kim, D. (2010). DETECTION OF NEW MUTATIONS IN NILOTINIB-TREATED PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. In HAEMATOLOGICA Vol. 95 (pp. 62). Barcelona, SPAIN: FERRATA STORTI FOUNDATION.
2010 Morley, A., Bartley, P., Ross, D., Latham, S., Budgen, B., Hughes, E., . . . Hughes, T. (2010). Monitoring of CML by DNA qPCR. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 12 (pp. 868). San Jose, CA: AMER SOC INVESTIGATIVE PATHOLOGY, INC.
2010 Stein, A., Shou, Y., Bottino, D., Chia, Y., Woodman, R., Martinelli, G., . . . Radich, J. (2010). RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB. In HAEMATOLOGICA Vol. 95 (pp. 56). Barcelona, SPAIN: FERRATA STORTI FOUNDATION.
2010 Hughes, T., Kim, D., Martinelli, G., Branford, S., Mueller, M., Beppu, L., . . . Hochhaus, A. (2010). EARLY MOLECULAR RESPONSE TO NILOTINIB IN PATIENTS WHO FAILED IMATINIB IS ASSOCIATED WITH A HIGHER PROBABILITY OF CYTOGENETIC RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML). In HAEMATOLOGICA Vol. 95 (pp. 54). Barcelona, SPAIN: FERRATA STORTI FOUNDATION.
WoS1
2010 Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T., Radich, J., . . . Kim, D. (2010). BCR-ABL MUTATION ANALYSIS USING BOTH ASO-PCR AND DIRECT SEQUENCING IN NEW CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH SUBOPTIMAL RESPONSE OR TREATMENT FAILURE FROM IMATINIB TREATMENT. In HAEMATOLOGICA Vol. 95 (pp. 344-345). FERRATA STORTI FOUNDATION.
2009 Saglio, G., Hochhaus, A., Martinelli, G., Gottardi, E., Soverini, S., Branford, S., . . . Kim, D. (2009). DYNAMICS OF CYTOGENETIC AND MOLECULAR RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E255K/V, Y253H, AND F359C/V. In HAEMATOLOGICA Vol. 94 (pp. 261). Berlin, GERMANY: FERRATA STORTI FOUNDATION.
2009 Mueller, M. C., Cross, N. C. P., Erben, P., Schenk, T., Ernst, T., Hehlmann, R., . . . Hochhaus, A. (2009). Harmonization of Molecular Monitoring of CML Therapy in Europe - Perspective of Widespread Competence in <i>BCR</i>-<i>ABL</i> Quantification.. In BLOOD Vol. 114 (pp. 1026). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS1
2009 Martinelli, G., Kim, D. W., Saglio, G., Branford, S., Erben, P., Gottardi, E., . . . Radich, J. (2009). RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E25SK/V, Y253H, AND F359C/V. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 94 (pp. 258-259). Berlin, GERMANY: FERRATA STORTI FOUNDATION.
WoS1
2009 Martinelli, G., Kim, D., Saglio, G., Branford, S., Erben, P., Gottardi, E., . . . Radich, J. (2009). RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E255K/V, Y253H, AND F359C/V. In HAEMATOLOGICA Vol. 94 (pp. 258-259). FERRATA STORTI FOUNDATION.
WoS1
2009 Baccarani, M., Druker, B. J., Cortes-Franco, J., Hughes, T. P., Kim, D. -W., Pane, F., . . . Guilhot, F. (2009). 24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 114 (pp. 142-143). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12
2009 Osborn, M. P., Branford, S., White, D. L., Seymour, J. F., Columbus, R., Taylor, K., . . . Hughes, T. P. (2009). Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.. In BLOOD Vol. 114 (pp. 461-462). New Orleans, LA: AMER SOC HEMATOLOGY.
2009 Esposito, N., Quintarelli, C., Colavita, I., Izzo, B., Peluso, A. L., Ruoppolo, M., . . . Pane, F. (2009). Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. In BLOOD Vol. 114 (pp. 871-872). New Orleans, LA: AMER SOC HEMATOLOGY.
2009 Radich, J. P., Martinelli, G., Hochhaus, A., Gottardi, E., Soverini, S., Branford, S., . . . Saglio, G. (2009). Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.. In BLOOD Vol. 114 (pp. 464-465). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS1
2009 Osborn, M. P., White, D. L., Saunders, V. A., Cambareri, B., Branford, S., Menelaou, A., . . . Hughes, T. P. (2009). Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.. In BLOOD Vol. 114 (pp. 465). New Orleans, LA: AMER SOC HEMATOLOGY.
2009 Branford, S., Hochhaus, A., Mueller, M., Bahceci, E., Ploughman, L., Mukhopadhyay, J., & Hughes, T. (2009). Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.. In BLOOD Vol. 114 (pp. 1270-1271). New Orleans, LA: AMER SOC HEMATOLOGY.
2009 Branford, S., Kim, D. -W., Soverini, S., Gottardi, E., Beppu, L., Mueller, M. C., . . . Hochhaus, A. (2009). Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 114 (pp. 1275-1276). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS1
2008 Branford, S., Lawrence, R., Grigg, A., Seymour, J. F., Schwarerl, A., Arthur, C., . . . Hughes, T. (2008). Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response. In BLOOD Vol. 112 (pp. 735-736). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS3
2008 Esposito, N., Quarantelli, F., Luciano, L., Izzo, B., Peluso, A. L., Picardi, M., . . . Pane, F. (2008). The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. In BLOOD Vol. 112 (pp. 404). San Francisco, CA: AMER SOC HEMATOLOGY.
2008 Hughes, T. P., Hochhaus, A., Branford, S., Mueller, M. C., Foroni, L., Druker, B. J., . . . Goldman, J. M. (2008). Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). In BLOOD Vol. 112 (pp. 129-130). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS11
2008 Hochhaus, A., Kim, D. -W., Martinelli, G., Hughes, T. P., Soverini, S., Branford, S., . . . Radich, J. P. (2008). Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 112 (pp. 1103-1104). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS2
2008 Hochhaus, A., Mueller, M. C., Radich, J., Branford, S., Hanfstein, B., Rousselot, P., . . . Hughes, T. P. (2008). Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib. In BLOOD Vol. 112 (pp. 400). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS4
2008 Cortes, J., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D. -W., . . . Hughes, T. P. (2008). A Phase III, Randomized. Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (1M) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. In BLOOD Vol. 112 (pp. 130-131). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS14
2008 Cross, C., Hochhaus, A., Mueller, M., Saglio, G., Branford, S., Hughes, T., . . . White, H. (2008). DEVELOPMENT OF PROTOTYPE REFERENCE MATERIALS FOR BCR-ABL QUANTITATIVE RT-PCR. In HAEMATOLOGICA Vol. 93 (pp. 54). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2008 Zhang, T., Nwachukwu, B., Grenier, S., Wei, C., Branford, S., & Kamel-Reid, S. (2008). Assessment of Quality Controls and Establishment of a Conversion Factor for Monitoring BCR-ABL1 Transcripts in CML. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 10 (pp. 583). Grapevine, TX: ELSEVIER SCIENCE INC.
2008 Morley, A. A., Bartley, P., Ross, D. M., Latham, S., Martin-Harris, H., Budgen, B., . . . Hughes, T. (2008). DNA-Based Monitoring of Minimal Residual Disease(MRD) in Chronic Myeloid Leukemia(CML). In BLOOD Vol. 112 (pp. 406). San Francisco, CA: AMER SOC HEMATOLOGY.
2008 Ross, D. M., Grigg, A., Schwarer, A., Arthur, C., Loftus, K., Mills, A. K., . . . Hughes, T. (2008). The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early. In BLOOD Vol. 112 (pp. 402-403). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS10
2008 Mueller, M., Erben, P., Saglio, G., Branford, S., Hanfstein, B., Gosenca, D., . . . Hochhaus, A. (2008). EUROPEAN STANDARDIZATION OF BCR-ABL MRNA QUANTIFICATION. In HAEMATOLOGICA Vol. 93 (pp. 61). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2008 Branford, S., Lawrence, R., Fletcher, L., Field, C., Rudzki, Z., & Hughes, T. (2008). The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening. In BLOOD Vol. 112 (pp. 128). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS2
2008 Radich, J., Kim, D. -W., Martinelli, G., Soverini, S., Branford, S., Mueller, M., . . . Saglio, G. (2008). RESPONSE TO NILOTINIB IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) ACCORDING TO BCR-ABL MUTATIONS AT BASELINE. In HAEMATOLOGICA Vol. 93 (pp. 55). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
WoS3
2008 Usuki, K., Urabe, A., Tojo, A., Maeda, Y., Kobayashi, Y., Jinnai, I., . . . Naoe, T. (2008). A PHASE I/II STUDY OF NILOTINIB IN JAPANESE PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) OR RELAPSED/REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). In HAEMATOLOGICA Vol. 93 (pp. 433-434). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2007 Mueller, M. C., Branford, S., Radich, J., Shah, N., Erben, P., Ernst, T., . . . Hochhaus, A. (2007). Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 127). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS4
2007 Soverini, S., Saglio, G., Branford, S., Radich, J., Kim, D. W., Hughes, T., . . . Martinelli, G. (2007). In patients with chronic myelogeneous leukemia (CML), response dynamics to nilotinibafter imatinib failure depend on thetype of BCR-ABL mutations. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 320). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS1
2007 Ross, D., Bartley, P. A., Morley, A. A., Seymour, J. F., Branford, S., & Hughes, T. P. (2007). Detection of patient-specific BCR-ABL genomic dna in cml patients with no detectable BCR-ABL by quantitative reverse transcriptase PCR. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 212). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS1
2007 Toplin, J., Fuller, C., Fletcher, L., Wong, S., Maslak, P., Cortes, J., . . . Beillard, E. (2007). An MMR control RNA for reliable monitoring of BCR-ABL transcripts in treated CML patients. In BLOOD Vol. 110 (pp. 863A-864A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI
2007 Hughes, T., Saglio, G., Martinelli, G., Kim, D. -W., Soverini, S., Mueller, M., . . . Hochhaus, A. (2007). Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. In BLOOD Vol. 110 (pp. 101A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS13
2007 Branford, S., Fletcher, L., Cross, N. C. P., Hochhaus, A., Mueller, M. C., Kim, D. -W., . . . Hughes, T. (2007). Validation of the international scale for measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors. In BLOOD Vol. 110 (pp. 307A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS1
2007 Hochhaus, A., Branford, S., Radich, J., Mueller, M. C., Shah, N., Erben, P., . . . Hughes, T. (2007). Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
WoS3
2007 Mueller, M. C., Branford, S., Radich, J., Kim, D. W., Martinelli, G., Saglio, G., . . . Hochhaus, A. (2007). Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
WoS4
2007 Saglio, G., Kim, D. -W., Hochhaus, A., Soverini, S., Erben, P., Branford, S., . . . Radich, J. (2007). Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance. In BLOOD Vol. 110 (pp. 576A-577A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS4
2007 Branford, S., Shou, Y., Lawrence, R., Rudzki, Z., & Hughes, T. (2007). The P-loop mutations Y253H and E255K/V may develop more frequently than T315I during nilotinib therapy after imatinib failure and are associated with progression in patients with Ph-positive leukemia. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 337-338). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS5
2006 Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Lynch, K., & Hughes, T. (2006). Increasing frequency and marked stability of complete molecular response is observed in imatinib-treated CML patients with long-term follow up.. In BLOOD Vol. 108 (pp. 131A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS4
2006 Hochhaus, A., Erben, P., Branford, S., Radich, J., Kim, D. W., Martinelli, G., . . . Baccarani, M. (2006). Hematologic and cytogenetic response dynamics to nilotinib (AMN107) depend on the type of BCR-ABL mutations in patients with chronic myelogeneous leukemia (CML) after imatinib failure.. In BLOOD Vol. 108 (pp. 225A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS4
2006 Shah, N. P., Skaggs, B., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2006). The most common dasatinib-resistant BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: Rationale for early combination kinase inhibitor therapy.. In BLOOD Vol. 108 (pp. 617A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS2
2006 Branford, S., Hughes, T., Stylian, S., Schwarer, A. P., Arthur, C., Filshie, R., . . . Taylor, K. M. (2006). Significant reduction of BCR-ABL transcripts after switching to imatinib therapy in patients with CML and complete or near-complete cytogenetic responses to interferon-alpha (IFN).. In BLOOD Vol. 108 (pp. 607A-608A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS1
2006 Shah, N. P., Skaggs, B., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2006). Sequential kinase inhibitor therapy in CML patients can select for cells harboring compound BCR-ABL kinase domain mutations with increased oncogenic potency: Rationale for early combination therapy of ABL kinase inhibitors.. In BLOOD Vol. 108 (pp. 225A-226A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS4
2006 Branford, S., Cross, N. C. P., Hochhaus, A., Radich, J., Saglio, G., Kim, D. W., . . . Hughes, T. (2006). First results from a collaborative initiative to develop an international scale for the measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors.. In BLOOD Vol. 108 (pp. 221A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS1
2006 Kaeda, J., Hochhaus, A., Radich, J., Branford, S., So, C., Gathmann, I., . . . Hughes, T. (2006). Patients with chronic phase CML in the IRIS study who receive imatinib mesylate (IM) 2nd line after prior IFN/Ara-C have sustained complete cytogenetic and major molecular response rates similar to 1st line IM patients.. In BLOOD Vol. 108 (pp. 607A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS2
2006 Ross, D. M., Hughes, T. P., & Branford, S. (2006). Reverse transcription with a random pentadecamer primer increases the sensitivity of quantitative PCR for BCR-ABL.. In BLOOD Vol. 108 (pp. 662A-663A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI
2005 Branford, S., Rudzki, Z., Lynch, K., & Hughes, T. (2005). Pre-imatinib factors can be used to define the risk of BCR-ABL mutations for patients with CML in chronic phase and identify a minority who should have regular mutation screening.. In BLOOD Vol. 106 (pp. 314A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS2
2005 Hughes, T. P., Branford, S., Reynolds, J., Koelmeyer, R., Seymour, J., Taylor, K., . . . Grigg, A. (2005). Maintenance of imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point.. In BLOOD Vol. 106 (pp. 51A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS4
2005 Oehler, V., Branford, S., Pogosova-Agadjanyan, E., Shah, N., Sawyers, C., Mao, M., . . . Radich, J. (2005). Gene expression signatures associated with treatment and resistance to imatinib mesylate in chronic myeloid leukemia patients.. In BLOOD Vol. 106 (pp. 131A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS2
2005 Goldman, J. M., Hughes, T., Radich, J., Branford, S., Hochhaus, A., So, C., . . . Kaeda, J. (2005). Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS study.. In BLOOD Vol. 106 (pp. 51A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS17
2005 Shah, N. P., Nicoll, J. M., Branford, S., Hughes, T. P., Paquette, R. L., Talpaz, M., . . . Sawyers, C. L. (2005). Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: Rationale for combination tyrosine kinase inhibitor therapy.. In BLOOD Vol. 106 (pp. 318A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS11
2005 White, D. L., Saunders, V. A., Branford, S., Lynch, K., To, L. B., & Hughes, T. P. (2005). The in-vivo level of imatinib induced kinase inhibition achieved in de-novo CML patients during the first 28 days of therapy is a powerful predictor of molecular outcome.. In BLOOD Vol. 106 (pp. 132A). Atlanta, GA: AMER SOC HEMATOLOGY.
2004 White, D. L., Saunders, V. A., Branford, S., Lyons, B., & Hughes, T. P. (2004). The combination of intrinsic sensitivity to imatinib and Sokal prognostic score is strongly predictive of molecular response in newly diagnosed CML patients treated with imatinib.. In BLOOD Vol. 104 (pp. 288A-289A). San Diego, CA: AMER SOC HEMATOLOGY.
2004 Shah, N. P., Branford, S., Hughes, T. P., Nicoll, J. M., Decillis, A. P., & Sawyers, C. L. (2004). Major cytogenetic responses to BMS-354825 in patients with chronic myeloid leukemia are associated with a one to two log reduction in <i>BCR</i>-<i>ABL</i> transcript.. In BLOOD Vol. 104 (pp. 288A). San Diego, CA: AMER SOC HEMATOLOGY.
WoS4
2004 Fossey, S. C., Ferreira-Gonzalez, A., Branford, S., Hughes, T. P., Garrett, C. T., Dumur, C. I., . . . Vnencak-Jones, C. L. (2004). Is standardization of quantitative RT-PCR assays for BCRABL transcript detection possible?. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 6 (pp. 415). Los Angeles, CA: AMER SOC INVESTIGATIVE PATHOLOGY, INC.
2004 Hughes, T., Branford, S., Reynolds, J., Seymour, J., Taylor, K., Guzzo-Pernell, N., . . . Grigg, A. (2004). Higher-dose imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase; Cytogenetic response rates at 12 months are superior to IRIS.. In BLOOD Vol. 104 (pp. 286A). San Diego, CA: AMER SOC HEMATOLOGY.
WoS8
2004 Paschka, P., Branford, S., Lorentz, C., Hehlmann, R., Hughes, T., & Hochhaus, A. (2004). Comparison of "log reduction from median pretherapeutic value" vs ratio BCR-ABL/ABL to express the therapeutic response in CML patients.. In BLOOD Vol. 104 (pp. 289A-290A). San Diego, CA: AMER SOC HEMATOLOGY.
WoS4
2004 Branford, S., Rudzki, Z., Grigg, A., Seymour, J., Browett, P., Taylor, K., . . . Hughes, T. (2004). The frequency of detection of BCR-ABL mutations in imatinib treated patients with chronic phase CML who attain a complete cytogenetic response (CCR) does not diminish with increasing duration of CCR but the associated loss of response is usually gradual. In BLOOD Vol. 104 (pp. 81A). San Diego, CA: AMER SOC HEMATOLOGY.
WoS1
2004 Branford, S., Rudzki, Z., Grigg, A., Seymour, J. F., Taylor, K., Browett, P., . . . Hughes, T. (2004). BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a major molecular response. In BLOOD Vol. 104 (pp. 82A). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS7
2003 Radich, J., Gathmann, I., Kaeda, J., Goldman, J. M., Branford, S., Hochhaus, A., . . . Hughes, T. (2003). Molecular responses to imatinib and interferon plus ara-c in newly diagnosed CML: Efficacy of imatinib on patients after cross-over from interferon therapy and prognostic importance of molecular responses on long-term outcomes.. In BLOOD Vol. 102 (pp. 182A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
2003 Gabert, J., Silvy, M., Heath, A., Arlinghaus, R., Branford, S., Barbany, G., . . . Saldanha, J. (2003). Biological reference materials for <i>BCR ABL</i> RNA detection by RQ PCR assays for therapeutic monitoring and optimization.. In BLOOD Vol. 102 (pp. 373A-374A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
WoS1
2003 Hui, C. H., Goh, K., White, D., Branford, S., Grigg, A., Seymour, J., . . . Hughes, T. P. (2003). Mobilization of CD34+ cells from chronic myeloid leukemia patients achieving CCR on imatinib; safety and efficacy using filgrastim with or without continuation of imatinib. In BONE MARROW TRANSPLANTATION Vol. 31 (pp. S50). ISTANBUL, TURKEY: NATURE PUBLISHING GROUP.
2003 Hughes, T. P., Branford, S., Matthews, J., Seymour, J., Taylor, K., Guzzo-Pernell, N., . . . Grigg, A. (2003). Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase.. In BLOOD Vol. 102 (pp. 31A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
WoS16
2003 Branford, S., Rudzki, Z., Miller, B., Grigg, A., Seymour, J. F., Schwarer, A., . . . Hughes, T. P. (2003). Mutations in the catalytic core (P-Loop) of the BCR-ABL kinase domain of imatinib-treated chronic myeloid leukemia patients in chronic phase are strongly associated with imminent progression to blast crisis.. In BLOOD Vol. 102 (pp. 71A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
WoS3
2003 Branford, S., Rudzki, Z., Grigg, A., Seymour, J. F., Taylor, K., Herrmann, R., . . . Hughes, T. P. (2003). The incidence of BCR-ABL kinase mutations in chronic myeloid leukemia patients is as high in the second year of imatinib therapy as the first but survival after mutation detection is significantly longer for patients with mutations detected in the second year of therapy.. In BLOOD Vol. 102 (pp. 414A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
WoS6
2003 Taylor, K. M., Branford, S., Hughes, T., Schwarer, A., Arthur, C., Filshie, R., . . . Josephsen, A. (2003). Imatinib produces substantial molecular remissions in interferon-treated chronic phase (CP) chronic myeloid leukemia (CML) in longstanding complete or near complete cytogenetic remission (CCyR) - An Australasian leukemia and lymphoma group (ALLG) study.. In BLOOD Vol. 102 (pp. 907A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
2002 Hughes, T., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Capdeville, R., . . . Radich, J. (2002). Molecular responses to imatinib (STI571) or interferon plus Ara-C as initial therapy for CML; Results in the IRIS study.. In BLOOD Vol. 100 (pp. 93A-94A). PHILADELPHIA, PENNSYLVANIA: AMER SOC HEMATOLOGY.
WoS23
2002 Branford, S., Walsh, S., Rudzki, Z., Grigg, A., Taylor, K., Durrant, S., . . . Hughes, T. (2002). Imatinib produces significantly superior molecular responses compared to interferon plus low dose ARA-C in patients with newly diagnosed chronic myeloid leukaemia in chronic phase.. In BLOOD Vol. 100 (pp. 96A). PHILADELPHIA, PENNSYLVANIA: AMER SOC HEMATOLOGY.
WoS5
2002 Branford, S., Walsh, S., Rudzki, Z., Grigg, A., Taylor, K., Herrmann, R., . . . Hughes, T. (2002). BCR-ABL kinase domain mutations in CML patients on imatinib: Incidence is correlated with duration of CML and mutations in the P-loop may be indicative of a poor outcome.. In BLOOD Vol. 100 (pp. 367A). PHILADELPHIA, PENNSYLVANIA: AMER SOC HEMATOLOGY.
WoS2

Year Citation
2019 Yeung, D. T., Grigg, A., Shanmuganathan, N., Solterbeck, A. C., White, D. L., Branford, S., . . . Hughes, T. P. (2019). Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI
2019 Yeung, D. T., Shanmuganathan, N., Grigg, A., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2019). Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI WoS2
2018 Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS8
2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition.
2017 Yeung, D., Grigg, A., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2017). Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
2017 Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J., Saunders, V. A., Prime, J. A., . . . Ross, D. M. (2017). COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION.
2016 Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA.
2016 Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD.
2016 Cross, N., White, H., Ernst, T., Welden, L., Saglio, G., Mahon, F. X., . . . Branford, S. (2016). DEVELOPMENT AND EVALUATION OF A MR1-MR4.5 SECONDARY LYOPHILIZED CELL REFERENCE PANEL FOR BCR-ABL1 QUANTIFICATION ON THE INTERNATIONAL SCALE. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2015 Rivera, V. M., Branford, S., Nicolini, F. E., Pritchard, J. R., Cozgit, J. M., Kern, W., . . . Haferlach, T. (2015). A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
2015 Branford, S., Yeung, D., Altamura, H., Seymour, J. F., Ross, D. M., & Hughes, T. (2015). BCR-ABL LEVELS AT LANDMARK TIMEPOINTS BETWEEN 1-3 YEARS OF IMATINIB ARE PREDICTIVE OF TIME TO A DEEP MOLECULAR RESPONSE AND CAN GUIDE THERAPY SWITCH DECISIONS WHERE TKI DISCONTINUATION IS THE GOAL. Poster session presented at the meeting of HAEMATOLOGICA. Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
2014 Branford, S., Yeung, D., Ross, D., Parker, W., Braley, J., Seymour, J., & Hughes, T. (2014). The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment. Poster session presented at the meeting of Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
2014 Yeung, D. T., Vidovic, L., Tang, C., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. M. (2014). KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY.
2014 Parker, W. T., Phillis, S. R., Yeung, D. T., Lawrence, D., Schreiber, A., Wang, P., . . . Branford, S. (2014). Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY.
DOI WoS4
2014 Casolari, D. A., Iarossi, D. G., Butcher, C. M., Bray, S. C., Parker, W. T., Hahn, C. N., . . . D'Andrea, R. J. (2014). Aberrant activation of epidermal growth factor receptor in MPN may respond to the kinase inhibitor gefitinib. Poster session presented at the meeting of Blood. US: American Society of Hematology.
2014 Branford, S., Yeung, D., Parker, W. T., Purins, L., Braley, J., Seymour, J. F., . . . Hughes, T. P. (2014). PROGNOSIS FOR CML PATIENTS WITH &gt;10% BCR-ABL AFTER 3 MONTHS OF IMATINIB DEPENDS ON THE INITIAL RATE OF BCR-ABL DECLINE. Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION.
2014 Torra, O. S., Beppu, L., Branford, S., Fletcher, L., Ted, G., Paguirigan, A. L., . . . Radich, J. P. (2014). Paper or Plastic: RT-PCR of BCR-ABL from Blood Spots Stored and Shipped on Paper. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY.
2013 Parker, W., Yeoman, A., Altamura, H., Roberts, N., Yeung, D., Jamison, B., . . . Branford, S. (2013). Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome. Poster session presented at the meeting of Blood. Amer Soc Hematology.
2013 Deininger, M., Shah, N., Cortes, J., Kim, D. W., Nicolini, F., Talpaz, M., . . . Branford, S. (2013). Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). Poster session presented at the meeting of Blood. Amer Soc Hematology.
WoS3
2013 Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2013). PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations. Poster session presented at the meeting of Oral Sessions from the 55th ASH Annual Meeting and Exhibition, as published in Blood. New Orleans, Louisiana: American Society of Hematology.
2012 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS8
2012 Branford, S., Ross, D., Prime, J., Field, C., Altamura, H., Yeoman, A., . . . Hughes, T. (2012). Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable <i>BCR</i>-<i>ABL1</i>, a Criterion for Imatinib Discontinuation in Patients with CML. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS6
2012 Parker, W. T., Yeoman, A. L., Jamison, B. A., Yeung, D. T., Scott, H. S., Hughes, T. P., & Branford, S. (2012). The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI
2012 Smith, C. C., Brown, M., Parker, W. T., Lin, K., Travers, K., Wang, S., . . . Shah, N. (2012). Single Molecule Real Time (SMRT (TM)) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.

  • Defining genomic mechanisms associated with treatment response, drug resistance and early blast crisis in chronic myeloid leukaemia, NHMRC - Research Fellowship, 01/01/2017 - 31/12/2021

  • Defining genomic mechanisms associated with tyrosine kinase inhibitor response, drug resistance, prognosis and progression in chronic myeloid leukaemia, Central Adelaide Local Health Network Incorporated, 21/02/2018 - 20/02/2021

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor Genomic Drivers and Therapeutic Vulnerabilities in Hematologic Malignancy Progression Doctor of Philosophy Doctorate Full Time Ms Yang Zhang
2025 Co-Supervisor Genomic Drivers and Therapeutic Vulnerabilities in Hematologic Malignancy Progression Doctor of Philosophy Doctorate Full Time Ms Yang Zhang
2024 Co-Supervisor The burden of cure: Secondary malignancy after allogeneic haematopoietic stem cell transplant Doctor of Philosophy Doctorate Full Time Miss Alia Elizabeth Cibich
2024 Co-Supervisor Modelling resistant mutations in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Zuhal Naderi
2024 Co-Supervisor The burden of cure: Secondary malignancy after allogeneic haematopoietic stem cell transplant Doctor of Philosophy Doctorate Full Time Miss Alia Elizabeth Cibich
2024 Co-Supervisor Modelling resistant mutations in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Zuhal Naderi
2022 Principal Supervisor - Doctor of Philosophy Doctorate Full Time Ms Muneeza Maqsood
2021 Principal Supervisor Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Part Time Miss Adelina Catherina B. Fernandes
2021 Principal Supervisor Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Miss Adelina Catherina B. Fernandes

Date Role Research Topic Program Degree Type Student Load Student Name
2012 - 2016 Principal Supervisor Prognostic Markers Associated With Tyrosine Kinase Inhibitor Treatment Response and Maintenance of Treatment Free Remission in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Prof David Yeung
2006 - 2009 Co-Supervisor Minimal Residual Disease in Chronic Myeloid Leukaemia after Imatinib Treatment Doctor of Philosophy Doctorate Full Time Dr David Ross

Connect With Me

External Profiles

Other Links